The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer.

The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Abstract Text:

Silvia Franceschi,

Every year approximately half a million women worldwide develop cervical cancer (CC) of whom 80% live in poor countries where population-based screening programmes are virtually non-existent. The role of sexually transmitted agents in the aetiology of cervical cancer has been suspected for more than a century, but knowledge in this field has rapidly expanded only in the last 20 years, after major improvements were made in detection methods for human papillomavirus (HPV). A dozen types of HPV have been identified in 99% of biopsy specimens from CC worldwide and the relative risk estimates for HPV in case-control studies of CC are in the 50 to 100 range. A meta-analysis done at the International Agency for Research on Cancer (IARC) included a total of 10,058 CC cases from 85 published studies. The most common HPV types identified in CC were, in order of decreasing prevalence, HPV 16, 18, 45, 31, 33, 58, 52, 35, 59, 56, 6, 51, 68, 39, 82, 73, 66 and 70. Over two-thirds of CC cases were associated with an infection of either HPV 16 (51.0%) or HPV 18 (16.2%). Despite the overwhelming importance of HPV, other factors contribute to the rare occurrence of CC after HPV infection. Nine case-control studies from the IARC have confirmed the adverse effect of long-term use of oral contraceptives, high parity, smoking and sexually transmitted infections (i.e. Chlamydia trachomatis and herpes simplex virus-2) after adjustment for, or stratification by, HPV infection. Ten surveys of HPV infection in population-based samples of approximately 15,000 women in four continents have shown that: (1) the prevalence of HPV infection varies greatly (between 2% and nearly 30%); and (2) the age distribution also varies widely, pointing to cohort effects. There is no effective medical treatment for HPV, but a prophylactic vaccine, based on late (L) 1 HPV 16 proteins, has been shown to be safe, highly immunogenic and efficacious in preventing persistent HPV infections. A multivalent vaccine against the most common oncogenic HPV types may thus ultimately represent the most effective way to prevent CC worldwide either alone, or in combination with screening. It may, however, take several years before this approach becomes a reality. Thus, early detection of CC precursor lesions by screening, and their treatment, will remain the most important measures for the control of CC for the foreseeable future.

The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Publishing Authors By Initials

S Franceschi,

For similar neoplasms: neoplasms by site: urogenital neoplasms: genital neoplasms, female: uterine neoplasms: uterine cervical neoplasms research abstracts see: neoplasms: neoplasms by site: urogenital neoplasms: genital neoplasms, female: uterine neoplasms: uterine cervical neoplasms research

PUBMED ID PMID:

MEDLINE DATE:

The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Journal Published:

PUBLICATION TYPE: Review

Journal: Recent results in cancer research. Fortschritte de

VOLUME: 166

Page Numbers: 277-97

Journal Abbreviation: Recent Results Cancer Res.

ISSN: 0080-0015

DAY: 13

MONTH: 02

YEAR: 2005

The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Information

Number of References: 49

LANGUAGE: eng

NlmUniqueID: 44671

The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Keywords Mesh Terms:

KEYWORDS: Uterine Cervical Neoplasms

MESH TERMS: virology

Chemical & Substance for Abstract: The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer.

AFFILIATION: International Agency for Research on Cancer, 150 cours Albert Thomas, 69008 Lyon, France. franceschi@iarc.fr

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Recent Results Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer Related Publications

• A genetic-demographic approach reveals male-specific association between survival and tumor necrosis factor (a/g)-308 polymorphism.
• A novel mitochondrial DNA-like sequence insertion polymorphism in Intron I of the FOXO1A gene.
• Analysis of transcription factor interactions in osteoblasts using competitive chromatin immunoprecipitation.
• Back to the future: the ribosome as an antibiotic target.
• Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells.
• Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines.
• Common evolutionary origin of the immune and neuroendocrine systems: from morphological and functional evidence to in silico approaches.
• Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development.
• Daunorubicin and daunorubicinol tissue concentrations in gastric cancer patients after local administration of a liposomal preparation.
• Different types of cell death in organismal aging and longevity: state of the art and possible systems biology approach.
• Erythrocyte plasma membranes obtained from centenarians show different functional properties.
• Healing Cranial Defects with AdRunx2-transduced Marrow Stromal Cells.
• Human longevity within an evolutionary perspective: The peculiar paradigm of a post-reproductive genetics.
• Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland.
• Human papillomavirus types among women infected with HIV: a meta-analysis.
• Immunoproteasome in Macaca fascicularis: No Age-Dependent Modification of Abundance and Activity in the Brain and Insight into an in silico Structural Model.
• In vitro and in vivo synergistic interactions between the Runx2/Cbfa1 transcription factor and bone morphogenetic protein-2 in stimulating osteoblast differentiation.
• Incidence of primary liver cancer in Italy between 1988 and 2002: An age-period-cohort analysis.
• Inflammaging as a major characteristic of old people: can it be prevented or cured?
• Long-term immune-endocrine effects of bereavement: relationships with anxiety levels and mood.
• Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix.
• New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology.
• Paraoxonase 1: genetics and activities during aging.
• Plasma concentrations of interleukin-1-beta, interleukin-6 and tumor necrosis factor-alpha, and of their soluble receptors and receptor antagonist in anorexia nervosa.
• Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey.
• Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe.
• Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea.
• The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer.
• Use of a stringent dimerizer-regulated gene expression system for controlled BMP2 delivery.
• Usefulness of the comprehensive geriatric assessment in older patients with upper gastrointestinal bleeding: a two-year follow-up study.